KYNB · Kyntra Bio Inc
United States · RS rating 9 · As of 2026-10-14
| Price | 5.57 USD |
|---|---|
| 1-day change | -5.2% |
| RS rating (overall / 1M / 3M / 12M) | 9 / 7 / 15 / 14 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 4 / 13 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -107.1% |
| Sales growth Q/Q | +18.7% |
| Distance from 52-week high | +50.2% |
| Market cap (USD) | $28.4M |